Welcome readers,
This week we have 20 deals across 8 countries: 8 from the UK, 5 from Germany, 3 from the Netherlands, 2 from Ireland, and 1 each from Spain and Switzerland. And wait till you see these deals, which run the gamut from €200 million biomedical research facilities breaking ground near Bayer's Berlin campus to French investors snapping up Dutch science campuses, not to mention Life Science REIT's UK portfolio being broken up.
We also take a peek at the life sciences and healthcare buildings that dominate this year's awards from ULI Europe.
🔒 Paying subscribers get all 20 deals • Everyone else can explore 2 of them → Get full access by subscribing here.
— Stephen Ryan (connect with me on LinkedIn)
🔍 Do you need deeper insights into life sciences real estate?
In addition to our regular updates, we offer bespoke research and strategic analysis for investors and developers in the life sciences sector. Whether you’re evaluating an acquisition, tracking market trends, or need a custom report, our team can help you make informed decisions.
Get in touch to discuss how we can support your next project.
Featured article of the week
Life sciences buildings dominate ULI awards shortlist
Ten projects from across EMEA have been announced as ULI Europe Awards for Excellence finalists, with life sciences claiming three spots.
Deals
GERMANY BERLIN
Construction has commenced on the iQ space Berlin-Mitte biomedical research facility, developed by iQ spaces and UBS Asset Management with a value of approximately €200 million. The ten-storey building comprises 20,000 sq m of total space and is located near the Bayer Open Innovation Campus north of Berlin Central Station. Three lease agreements totalling 15,500 sq m were secured prior to construction commencement.
Would you like instant access to 1,200+ deals like these? Our data tool lets you filter, sort and search European life sciences transactions spanning 24 countries—whether you're tracking a single city or spotting market patterns others miss.
GERMANY COLOGNE
The Lipoid Group reached a milestone in 2025 with new logistics and production areas at its Cologne pharmaceutical facility ready for commissioning in 2026. The development spans more than 15,000 sq m and includes a modern production and laboratory complex, pharmaceutical warehouse, logistics and administration buildings, as well as a new steam generation and cooling water unit. The facility makes special fat-based ingredients that create tiny protective bubbles to safely deliver medicines and vaccines (like COVID mRNA vaccines) into the body.
👇 As a free member, you get access to two deals for free.
Upgrade now to access the full list (18 more deals this week).
